14 results
Esophageal Crohn's Disease Management Algorithm

Assess for Active Symptoms and for Stricturing/Fistulizing Disease
Stricturing DX:
 • Bx r/o
Crohn's Disease Management ... for Active Symptoms ... DX: • Bx r/o Malignancy ... Crohns #Disease #Management ... #IBD
Pre-Op Nutrition in IBD - IBD Algorithm

Dr. Wade Billings @wabillin

#PreOp #Preoperative #Nutrition #IBDAlgorithm #IBD #Algorithm #gastroenterology
Pre-Op Nutrition ... in IBD - IBD Algorithm ... Preoperative #Nutrition #IBDAlgorithm ... #IBD #Algorithm ... gastroenterology #management
Venous Thromboembolism (VTE) in IBD - IBD Algorithm

 • 2-3x risk VTE vs non-IBD
 • VTE/AT
- IBD Algorithm ... flare activity ... Thromboembolism #VTE #IBDAlgorithm ... #IBD #Algorithm ... gastroenterology #management
Fatigue and IBD Algorithm
 • 40-50% patients have fatigue despite clinical remission
 • Risk factors: BMI,
Pearls: • IDA and active ... NRH & Heme eval. re ... ileal Crohn's/resection ... have fatigue w/ active ... #management
Treatment Algorithm for First Time Pulmonary Embolism
 • Provoked
 • Unprovoked
 • Active Malignancy

By Carlin Rooke,
Treatment Algorithm ... Unprovoked • Active ... Malignancy By ... #PE #Pulmonary # ... #management #hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... #DOAC #VTE #Malignancy ... #Cancer #Algorithm ... Anticoagulation #Management ... #Hematology #Oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
for VTE in Malignancy ... incidental DVT or PE ... #DOAC #VTE #Malignancy ... Anticoagulation #Management ... #Hematology #Oncology
Relapsing Acute Severe Ulcerative Colitis - Management Algorithm
Loss of Response:
 • (Re)consult Colorectal Surgery
 • Assess
Ulcerative Colitis - Management ... Response: • (Re ... Assess Disease Activity ... #Colitis #UC #Management ... #Algorithm #IBD
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
terminal alveoli and are ... inhibitors • Injection ... Langerhans giant cells are ... tracheobronchial stenosis, malignancy ... TB #Diagnosis #Management
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
terminal alveoli and are ... inhibitors • Injection ... Langerhans giant cells are ... tracheobronchial stenosis, malignancy ... TB #Diagnosis #Management